Pulse Biosciences (NASDAQ:PLSE) Trading Up 7.1% - What's Next?

Key Points

• Pulse Biosciences' share price increased by 7.1% during mid-day trading, reaching a high of $16.42 before closing at $16.17.
• Oppenheimer has assumed coverage on Pulse Biosciences with an "outperform" rating and a target price of $22.00.
• Insider trading activity includes a significant sale by CTO Darrin Uecker, who sold 15,000 shares at an average price of $16.40.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report)'s share price was up 7.1% during mid-day trading on Wednesday . The stock traded as high as $16.42 and last traded at $16.17. Approximately 125,935 shares were traded during trading, a decline of 26% from the average daily volume of 170,938 shares. The stock had previously closed at $15.10.

Analysts Set New Price Targets

Separately, Oppenheimer assumed coverage on shares of Pulse Biosciences in a report on Monday, July 7th. They set an "outperform" rating and a $22.00 target price for the company.

Pulse Biosciences Price Performance

The business's fifty day simple moving average is $15.48 and its two-hundred day simple moving average is $16.99.

Insiders Place Their Bets

In other news, CTO Darrin Uecker sold 15,000 shares of Pulse Biosciences stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $16.40, for a total value of $246,000.00. Following the sale, the chief technology officer owned 137,872 shares in the company, valued at $2,261,100.80. This trade represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 71.50% of the company's stock.

Institutional Trading of Pulse Biosciences

Institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC grew its position in shares of Pulse Biosciences by 98.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock valued at $29,000 after purchasing an additional 838 shares during the period. AlphaQuest LLC boosted its holdings in Pulse Biosciences by 68.0% in the 1st quarter. AlphaQuest LLC now owns 3,116 shares of the company's stock valued at $50,000 after purchasing an additional 1,261 shares during the last quarter. PNC Financial Services Group Inc. purchased a new stake in shares of Pulse Biosciences in the 1st quarter valued at approximately $90,000. GAMMA Investing LLC raised its stake in shares of Pulse Biosciences by 2,203.1% in the 1st quarter. GAMMA Investing LLC now owns 6,034 shares of the company's stock valued at $97,000 after acquiring an additional 5,772 shares during the period. Finally, Farther Finance Advisors LLC raised its stake in shares of Pulse Biosciences by 24.6% in the 1st quarter. Farther Finance Advisors LLC now owns 8,998 shares of the company's stock valued at $143,000 after acquiring an additional 1,778 shares during the period. Institutional investors and hedge funds own 76.95% of the company's stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.